Skip to main content
Top
Published in: Current Hepatology Reports 4/2016

01-12-2016 | Hepatic Cancer (A Singal and A Mufti, Section Editors)

Expanded Criteria for Resection: Are Current Guidelines Too Conservative?

Authors: Tian Yang, Emmanuel Melloul, Parissa Tabrizian, Myron Schwartz

Published in: Current Hepatology Reports | Issue 4/2016

Login to get access

Abstract

The surgical treatment of hepatocellular carcinoma (HCC) relies on the guidelines edited by the American (AASLD) and Europe (EASL) societies, according to the evidence-based Barcelona clinic liver cancer (BCLC) staging system. One drawback of the BCLC system is that it is not acknowledged by surgeons. For patients with locally advanced HCC (BCLC stage B and C) treatments such as transarterial chemoembolization (TACE) and Sorafenib are preferred over surgery as they have shown survival benefits in nonrandomized series. While the BCLC management schema has been adopted into hepatology-driven Western guidelines, algorithms from Asian countries are advocating to extend the criteria for surgery in HCC. In this chapter, we will assess if the guidelines for resection are too restrictive in the management of HCC.
Literature
2.
go back to reference • Bruix J, Sherman M, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2. Updated information based on the AASLD guidelines. • Bruix J, Sherman M, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2. Updated information based on the AASLD guidelines.
3.
go back to reference • European Association for the Study of the Liver. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatology. 2012;56:908–43. EASL–EORTC CPG on the management of hepatocellular carcinoma provide recommendations based on the level of evidence and the strength of the data and the strength of recommendations. • European Association for the Study of the Liver. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatology. 2012;56:908–43. EASL–EORTC CPG on the management of hepatocellular carcinoma provide recommendations based on the level of evidence and the strength of the data and the strength of recommendations.
4.
go back to reference Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–53.CrossRefPubMed Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–53.CrossRefPubMed
5.
go back to reference • Llovet JM, Real MI, Montaña X, Planas R, Coll S, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9. RCT in patients with unresectable hepatocellular carcinoma and assement of survival benefits of TAE/TACE compared with conservative treatment. • Llovet JM, Real MI, Montaña X, Planas R, Coll S, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9. RCT in patients with unresectable hepatocellular carcinoma and assement of survival benefits of TAE/TACE compared with conservative treatment.
6.
go back to reference • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90. RCT in patients with advanced HCC and assessment of survival benefits of sorafenib vs. placebo. • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90. RCT in patients with advanced HCC and assessment of survival benefits of sorafenib vs. placebo.
7.
go back to reference Yin L, Li H, Li AJ, Lau WY, Pan ZY, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014;61:82–8.CrossRefPubMed Yin L, Li H, Li AJ, Lau WY, Pan ZY, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014;61:82–8.CrossRefPubMed
8.
go back to reference Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group. Ann Surg. 2013;257(5):929–37.CrossRefPubMed Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group. Ann Surg. 2013;257(5):929–37.CrossRefPubMed
9.
go back to reference Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65(16)30258-6. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65(16)30258-6.
10.
go back to reference Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146:1691–700.CrossRefPubMed Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146:1691–700.CrossRefPubMed
11.
go back to reference Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, et al. Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–74.CrossRefPubMedPubMedCentral Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, et al. Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–74.CrossRefPubMedPubMedCentral
12.
go back to reference Kokudo N, Hasegawa K, Akahane M, Igaki G, Izumi N, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 2015;45(2) Kokudo N, Hasegawa K, Akahane M, Igaki G, Izumi N, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 2015;45(2)
Metadata
Title
Expanded Criteria for Resection: Are Current Guidelines Too Conservative?
Authors
Tian Yang
Emmanuel Melloul
Parissa Tabrizian
Myron Schwartz
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 4/2016
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-016-0322-x

Other articles of this Issue 4/2016

Current Hepatology Reports 4/2016 Go to the issue

Hepatitis B (JK Lim, Section Editor)

Future Therapy for HBV: Role of Cell Cycle Inhibitors

Hepatitis B (JK Lim, Section Editor)

Current Management of Hepatitis B in 2016

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.